The estimated Net Worth of Mark Ajaeger Wilfred Ethree... is at least $120 millier dollars as of 7 December 2012. Mark Ethree owns over 2,416,918 units of Acelrx Pharmaceuticals Inc stock worth over $120,074 and over the last 12 years Mark sold ACRX stock worth over $0.
Mark has made over 1 trades of the Acelrx Pharmaceuticals Inc stock since 2012, according to the Form 4 filled with the SEC. Most recently Mark bought 2,416,918 units of ACRX stock worth $7,999,999 on 7 December 2012.
The largest trade Mark's ever made was buying 2,416,918 units of Acelrx Pharmaceuticals Inc stock on 7 December 2012 worth over $7,999,999. On average, Mark trades about 2,416,918 units every 0 days since 2012. As of 7 December 2012 Mark still owns at least 139,621 units of Acelrx Pharmaceuticals Inc stock.
You can see the complete history of Mark Ethree stock trades at the bottom of the page.
Over the last 14 years, insiders at Acelrx Pharmaceuticals Inc have traded over $25,363,406 worth of Acelrx Pharmaceuticals Inc stock and bought 5,245,025 units worth $26,783,172 . The most active insiders traders include Advisors Llcperceptive Life..., Advisors Llcedelman Josephp... et Mark Ajaeger Wilfred Ethree.... On average, Acelrx Pharmaceuticals Inc executives and independent directors trade stock every 63 days with the average trade being worth of $109,939. The most recent stock trade was executed by Vincent J. Angotti on 13 December 2023, trading 10,000 units of ACRX stock currently worth $7,300.
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Acelrx Pharmaceuticals Inc executives and other stock owners filed with the SEC include: